The frequency of uMRD in Japanese patients with CLL after 24 months of treatment with Venetoclax plus/minus Rituximab in the 2L+ in the real-world setting
Not Applicable
Recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Registration Number
- JPRN-UMIN000050967
- Lead Sponsor
- AbbVie GK
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 89
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with no data on information on the start and end dates or continuation of treatment with Venetocalx 2. Patients participating in other clinical trials
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The frequency of uMRD at 24 months (+3 months) of treatment with Venetoclax plus/minus Rituximab
- Secondary Outcome Measures
Name Time Method The frequency of L-MRD (Low-Minimal/Measurable Residual Disease) at 24 months (+3 months) of treatment with Venetoclax plus/minus Rituximab